BASKING RIDGE, N.J., Sept. 14, 2011 /PRNewswire/ — Regado
Biosciences, a privately held company pioneering the development of
antithrombotic aptamers with active control agents, announced that
Ellen McDonald, MBA, Senior Vice President and Chief Business
Officer, will be presenting at the Annual UBS Global Life Sciences
Conference at the Grand Hyatt New York in New York City on
Wednesday, September 21, 2011 at 3:30 p.m. EDT. The
presentation will include an overview of the Company’s pipeline
with emphasis on the lead development program, the innovative
anticoagulant system REG1, including a summary of the REG1 phase 2b
trial (RADAR) results.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company
pioneering a new therapeutic technology with the creation and
development of proprietary controllable aptamer drug systems.
Each system comprises a nuclease-stabilized RNA aptamer, the
therapeutic effect of which can be reversed partially or completely
in real time by its specific and complementary oligonucleotide
active control agent. This technology is being applied to
injectable antithrombotics (including anticoagulants and
antiplatelet agents) in the acute and sub-acute care cardiovascular
setting, a multi-billion dollar world-wide market in need of drugs
with improved safety profiles and a greater degree of therapeutic
control. The products in Regado’s pipeline are designed to
act as optimized antithrombotics, uniquely concomitantly minimizing
the risk of ischemia and bleeding, and, by allowing patient
specific tuning of the desired therapeutic effect, providing a safe
and unique approach to personalized medicine.
ABOUT REG1, REG2 and REG3
Regado’s lead program, the anticoagulant system REG1, consists
of two parenteral agents both administered by IV bolus, the first
being a potent highly selective Factor IXa inhibitor (pegnivacogin,
a.k.a. RB006)
‘/>”/>
